References
- Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow up. J Rheumatol 1984; 11 (2): 158–61
- Sherrer YS, Bloch DA, Mitchell DM, et al. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986; 29(4): 494–500
- Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis with in the first 2 years of disease. J Rheumatol 1989; 16(5): 585–91
- Chan KW, Felson DT, Yood RA, et al. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994; 37(6): 814–20
- Ferraccioli G, Salaffi F, Nervetti A, et al. Slow acting drugs: outcome no different than 15 years ago. (Letter) J Rheumatol 1990; 17(9): 1249–50
- Harris ED Jr. Rheumatoid arthritis. In: General principles of therapy. Philadelphia: Saunders, 1997: 317–23
- Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chronic Dis 1985; 38(12): 973–84
- Hill J, Bird HA, Hopkins R, et al. The development and use of Patient Knowledge Questionnaire in rheumatoid arthritis. Br J Rheumatol 1991; 30(1): 45–9
- Mills JA, Pinals RS, Ropes MW, et al. Value of bed rest in patients with rheumatoid arthritis. N Engl J Med 1971; 284(9): 453–8
- Gerber LH. Exercise and arthritis. Bull Rheum Dis 1990; 39(6): 1–9
- Tanner SB, Callahan LF, Panush R, et al. Dietary and allergic associations with rheumatoid arthritis: self report of 704 patients. Arthritis Care Res 1990; 3: 189
- Kremer JM, Bigauoette J, Michalek AV, et al. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1985; 1 (8422): 184–7
- Kremer JM, Jubiz W, Michalek A, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 1987; 106(4): 497–503
- Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs: clinical and immune correlates. Arthritis Rheum 1995; 38(8): 1107–14
- Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996; 26(l): 435–46
- Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992; 35(10): 1117–25
- O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxy chloroquine, or a combination of all three medications. N Engl J Med 1996; 334(20): 1287–91
- O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997; 40(5): 842–8
- Methotrexate-Cyclosporine Combination Study Group. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333(3): 137–41
- Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989; 16(5): 565–7
- Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33(10): 1449–61
- Paulus HE. Current controversies in rheumatology: the use of combinations of disease-modifying anti-rheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990; 33: 113